Veralox Therapeutics Inc. announced it raised $14.4 Million in an initial filing from an offering of $22.8 Million

Company

Location

About

VLX-1005 is a Phase 2 drug candidate indicated for heparin-induced thrombocytopenia (HIT). It comes with Orphan Drug and Fast Track designations, representing a crucial step in addressing a rare but serious condition. This asset aligns with Cadrenal's strategic vision to enhance its portfolio in the anticoagulation space and improve patient outcomes. The acquisition strengthens Cadrenal's market position considerably.